The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...

Meanwhile, Sanofi has selected a new clinical candidate from a five-year-old, $2 billion collaboration with Kymera focusing on MGD therapies that target IRAK4, being explored as a drug target for ...

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith Edmund Ingham Thu, Mar. 21, 2024 2 Comments ...

US biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which could be worth up to $2 billion.

Sanofi ADS has moved -0.7% over the last year, and the S&P 500 logged a change of 11.9% SNY has an average analyst rating of ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Sabic to close UK cracker, plastics recycler Novoloop raises funds, Kymera strikes molecular glue deal, and more ...

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

Kymera: Sanofi Ends KT-474 Work, Will Advance KT-485 Global News Select Jun 25, 2025, 6:01:00 AM INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY ...

TotalEnergies SE (EPA:TTEF) revealed on Friday that it has acquired a 25% interest in Block 53 offshore Suriname from Spain’s Moeve, formerly CEPSA.

UBS analyst Colin White maintained a Buy rating on Sanofi (SNYNF – Research Report) today. The company’s shares closed yesterday at $94.99. Don’t Miss TipRanks’ Half-Year ...

Boeing is entering a new phase of recovery that could support a market reassessment of its stock, according to analysts at Redburn.